Journal article
Attrition from Randomized Controlled Trials of Pharmacological Weight Loss Agents: A Systematic Review and Analysis
Obesity reviews, v 10(3), pp 333-341
May 2009
PMID: 19389060
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Clinical trials of obesity treatments have been limited by substantial dropout. Participant-level variables do not reliably predict attrition, and study-level variables have not yet been examined. We searched MEDLINE and identified 24 large randomized controlled trials of weight loss medications. These trials were comprised of 23 placebo and 32 drug groups. Two authors independently extracted the following for each treatment group: treatment received; design characteristics (inclusion of a lead-in period, selection of participants with weight-related comorbidities, study location, and number of study visits); sample characteristics (sample size, % female, and mean baseline age and BMI); and attrition (total, adverse event [AE] related, and non-AE-related) at 1 year. The primary outcome was total attrition, which was significantly related to treatment (i.e., 34.9%, 28.6%, 28.3%, and 35.1% in placebo, orlistat, sibutramine, and rimonabant groups, respectively,
p
< .0001). In adjusted multivariable models, total attrition was significantly lower in groups that completed a pre-randomization lead-in period than in those that did not (29.1% vs. 39.9%,
p
< .01). Gender also was significantly related to total attrition; groups with more women had higher dropout (
p
< .01). The pattern was similar for predicting non-AE-related attrition. Findings suggest ways to design studies that maximize retention.
Metrics
Details
- Title
- Attrition from Randomized Controlled Trials of Pharmacological Weight Loss Agents: A Systematic Review and Analysis
- Creators
- Anthony N Fabricatore - Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PennsylvaniaThomas A Wadden - Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PennsylvaniaReneé H Moore - Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PennsylvaniaMeghan L Butryn - Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PennsylvaniaElizabeth A Gravallese - Center for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PennsylvaniaNgozi E Erondu - Merck Research Laboratories, Rahway, New JerseySteven B Heymsfield - Merck Research Laboratories, Rahway, New JerseyAllison M Nguyen - Merck Research Laboratories, North Wales, Pennsylvania
- Publication Details
- Obesity reviews, v 10(3), pp 333-341
- Publisher
- Wiley
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Epidemiology and Biostatistics; Center for Weight, Eating and Lifestyle Science (WELL) [Historical]
- Web of Science ID
- WOS:000265511300010
- Scopus ID
- 2-s2.0-65349107671
- Other Identifier
- 991014878475904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Endocrinology & Metabolism